Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
出版年份 2012 全文链接
标题
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
作者
关键词
-
出版物
Journal of Oncology
Volume 2012, Issue -, Pages 1-9
出版商
Hindawi Limited
发表日期
2012-05-09
DOI
10.1155/2012/703858
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: A pooled subset analysis of two phase III studies
- (2011) Jacek Jassem et al. BREAST
- Breast cancer statistics, 2011
- (2011) Carol DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary
- (2010) E. Chuang et al. ANNALS OF ONCOLOGY
- Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
- (2010) Edith A. Perez et al. BREAST CANCER RESEARCH AND TREATMENT
- Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2010) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
- Human Microtubule-Associated-Protein Tau Regulates the Number of Protofilaments in Microtubules: A Synchrotron X-Ray Scattering Study
- (2009) M.C. Choi et al. BIOPHYSICAL JOURNAL
- A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial
- (2009) Stacy Moulder et al. BREAST CANCER RESEARCH AND TREATMENT
- Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase
- (2009) E. Alli et al. CANCER RESEARCH
- Discovery of Ixabepilone
- (2009) J. T. Hunt MOLECULAR CANCER THERAPEUTICS
- Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy
- (2009) V. Guarneri et al. ONCOLOGIST
- Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy
- (2008) Ahmad Awada et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical efficacy spectrum and pharmacokinetics of ixabepilone
- (2008) Francis Y. F. Lee et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models
- (2008) F. Y.F. Lee et al. CLINICAL CANCER RESEARCH
- Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
- (2008) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors
- (2008) E. Rivera et al. ONCOLOGIST
- Complementary dimerization of microtubule-associated tau protein: Implications for microtubule bundling and tau-mediated pathogenesis
- (2008) K. J. Rosenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started